respiratori
syncyti
viru
rsv
common
etiolog
bronchiol
highest
incid
infect
north
america
decemb
april
year
warmer
climat
first
present
rsv
tend
occur
earlier
fall
summer
month
north
america
bronchiol
lead
caus
hospit
infant
younger
year
age
estim
american
infant
hospit
year
ill
repres
approxim
children
affect
bronchiol
canada
unit
state
admiss
ill
increas
last
decad
associ
increas
morbid
cost
estim
annual
health
cost
associ
bronchiol
reach
billion
unit
state
bronchiol
viral
induc
bronchiolar
inflamm
clinic
manifest
close
resembl
older
child
asthma
much
debat
definit
bronchiol
clinic
diagnosi
reli
upon
clinician
judgment
present
sign
symptom
american
academi
pediatr
clinic
practic
guidelin
defin
bronchiol
constel
clinic
symptom
sign
includ
viral
upper
respiratori
prodrom
follow
increas
respiratori
effort
wheez
children
less
two
year
age
infant
bronchiol
often
abnorm
vital
sign
children
bronchiol
respiratori
rate
often
higher
breath
per
minut
often
heart
rate
increas
well
elev
bodi
temperatur
may
may
present
present
fever
may
reach
high
c
oxygen
satur
measur
puls
oximet
commonli
use
assess
children
bronchiol
although
ubiquit
health
care
set
puls
oximet
without
limit
misread
oxygen
satur
due
normal
monitor
variat
motion
artifact
poor
placement
clinician
must
take
care
confirm
hypoxem
read
puls
oximet
prior
initi
oxygen
therapi
one
clinic
sign
symptom
accur
diagnos
hypoxemia
studi
suggest
cyanosi
grunt
difficulti
feed
level
mental
alert
predict
manifest
urti
includ
mild
conjunct
otiti
media
pharyng
present
mani
patient
clinic
present
bronchiol
quit
variabl
time
patient
child
manifest
may
rang
mild
sign
respiratori
distress
transient
event
mucou
plug
way
apnea
respiratori
failur
excess
nasal
secret
may
lead
upper
airway
obstruct
inspiratori
expiratori
nois
auscult
increas
work
breath
manifest
nasal
flare
intercost
retract
subcost
retract
use
accessori
muscl
upon
auscult
diffus
bilater
wheez
crackl
often
present
expiratori
phase
respir
also
prolong
due
hyperinfl
lung
secondari
air
trap
uncommon
find
liver
spleen
palpabl
abdomin
exam
infant
bronchiol
ill
earli
childhood
key
assess
hydrat
feed
statu
child
bronchiol
done
inquiri
regard
total
volum
fluid
intak
number
wet
diaper
presenc
tear
child
activ
level
care
taken
address
fluid
intak
earli
child
cours
ill
increas
work
breath
combin
decreas
intak
rapidli
lead
dehydr
certain
underli
condit
predispos
child
turbul
cours
ill
bronchiol
inquir
child
medic
histori
care
taken
inquir
prematur
chronic
lung
diseas
cardiac
diseas
immunodefici
neuromuscular
disord
util
radiograph
diagnosi
bronchiol
limit
avail
radiograph
find
tend
nonspecif
includ
hyperinfl
patchi
atelectasi
occasion
peribronchi
infiltr
consolid
pleural
fluid
pneumonia
may
seen
respiratori
syncyti
viru
rsv
predomin
etiolog
agent
acut
viral
bronchiol
case
attribut
viru
nineti
percent
children
infect
rsv
year
age
unfortun
rsv
infect
result
longterm
immun
reinfect
commonli
experienc
throughout
childhood
adult
year
recent
notabl
increas
number
virus
recogn
etiolog
agent
bronchiol
due
great
part
avail
highli
sensit
molecular
amplificationbas
diagnost
test
virus
includ
rhinoviru
adenoviru
coronaviru
enteroviru
parainfluenza
viru
type
influenza
recent
identifi
human
metapneumoviru
hmpv
hmpv
new
paramyxoviru
first
isol
young
children
respiratori
tract
diseas
thought
respons
case
bronchiol
consid
second
common
caus
bronchiol
rsv
respiratori
virus
season
variat
occurr
peak
occurr
late
winterearli
spring
north
america
europ
slightli
rsv
peak
activ
patholog
acut
viral
bronchiol
character
extens
inflamm
airway
increas
mucu
product
airway
cell
necrosi
bronchoconstrict
rsv
common
infect
viru
bronchiol
bind
tolllik
epitheli
cell
fuse
membran
cell
membran
caus
direct
cellular
ciliari
damag
indirect
inflammatori
effect
respiratori
tract
infect
viru
usual
rsv
replic
caus
epitheli
cell
necrosi
ciliari
destruct
cell
destruct
trigger
inflammatori
respons
infiltr
submucosa
neutrophil
lymphocyt
fig
thick
mucu
plug
creat
increas
mucu
secret
goblet
cell
combin
desquam
epitheli
cell
mucu
plug
result
bronchiolar
obstruct
lead
airtrap
vari
degre
lobular
collaps
mechan
caus
ventilationperfus
mismatch
ultim
hypoxemia
immunopathogenesi
rsv
bronchiol
still
poorli
understood
seemingli
contradictori
evid
regard
role
cell
develop
rsv
bronchiol
studi
show
specif
cell
requir
patholog
actual
enhanc
sever
diseas
contrast
recent
studi
demonstr
cell
protect
rsvinduc
diseas
littl
doubt
cell
import
role
rsv
bronchiol
wit
rsv
vaccin
trial
inactiv
viral
vaccin
protect
immun
children
natur
infect
fact
paradox
led
sever
case
two
death
immun
consid
histor
issu
newer
emerg
evid
like
coexist
protect
diseasepromot
adapt
immun
mechan
play
futur
research
clarifi
appar
conundrum
diagnosi
bronchiol
essenti
base
upon
clinic
present
constel
present
sign
symptom
combin
patient
age
presenc
bronchiolitisrel
viru
commun
usual
rsv
make
diagnosi
like
laboratori
test
nasopharyng
aspir
bronchiolitisrel
virus
support
patient
diagnosi
aid
syndrom
surveil
help
inpati
bed
assign
see
chapter
case
bronchiol
clinic
diagnosi
adequ
viral
test
add
littl
routin
manag
blood
ga
capillari
venou
arteri
aid
assess
ga
exchang
acidosi
child
moder
sever
respiratori
distress
child
poor
oral
intak
sign
dehydr
one
assess
electrolyt
abnorm
extent
dehydr
measur
plasma
bun
creatin
electrolyt
perform
white
blood
cell
count
rang
low
normal
high
count
low
cellsmm
high
cellsmm
howev
laboratori
test
specif
bronchiol
singl
laboratori
test
confirm
rule
diagnosi
acut
viral
bronchiol
radiolog
test
mainli
form
chest
radiographi
commonli
perform
children
suspect
bronchiol
estim
children
present
emerg
depart
admit
inpati
ward
receiv
chest
radiograph
despit
high
frequenc
use
littl
evid
support
effect
practic
larg
survey
children
hospit
unit
state
perform
chest
radiograph
infant
bronchiol
associ
increas
likelihood
prescrib
antimicrobi
increas
length
stay
like
due
fact
bronchiolitisrel
atelectasi
difficult
distinguish
consolid
radiograph
studi
util
chest
radiograph
acut
bronchiol
includ
children
underw
radiographi
clinic
diagnosi
bronchiol
ninetythre
percent
patient
simpl
bronchiol
evid
imag
author
also
conclud
risk
airspac
diseas
particularli
low
children
hemoglobin
oxygen
satur
greater
mildmoder
distress
perform
typic
radiograph
child
bronchiol
demonstr
hyperinfl
flatten
diaphragm
peribronchi
infiltr
airway
wall
thicken
occasion
patchi
atelectasi
fig
current
evid
support
routin
use
radiograph
child
typic
bronchiol
benefit
evid
even
child
admit
consid
clinic
diagnosi
bronchiol
import
also
consid
reason
differenti
diagnos
caus
respiratori
distress
consid
includ
upper
airway
obstruct
eg
adenoid
hypertrophi
retropharyng
abscess
laryng
obstruct
eg
croup
foreign
bodi
asthma
pneumonia
metabol
disord
mimick
respiratori
diseas
eg
salicyl
poison
diabet
ketoacidosi
inborn
error
metabol
congest
heart
failur
eg
preexist
congenit
heart
condit
newonset
viral
myocard
parenchym
lung
diseas
eg
exacerb
cystic
fibrosi
congenit
lung
diseas
may
also
present
fashion
similar
bronchiol
may
exacerb
bronchiol
two
recent
comprehens
evidencebas
guidelin
diagnosi
manag
prevent
bronchiol
reassur
note
american
academi
pediatr
aap
scottish
intercollegi
guidelin
network
sign
perform
comprehens
review
literatur
led
conclus
cornerston
bronchiol
treatment
remain
support
care
infant
mild
bronchiol
requir
specif
treatment
success
treat
home
infant
moder
sever
respiratori
distress
often
hospit
approxim
children
bronchiol
great
variabl
clinic
approach
treatment
bronchiol
despit
four
decad
research
much
confus
controversi
regard
treatment
common
lifethreaten
condit
follow
section
attempt
summar
current
avail
medic
literatur
order
support
evidencebas
decis
make
previous
state
monitor
fluid
intak
hydrat
statu
key
assess
infant
bronchiol
infant
breastfe
highli
encourag
contribut
hydrat
confer
immunolog
advantag
breast
milk
shown
neutral
activ
rsv
contain
rsv
immunoglobulin
g
well
estim
approxim
children
admit
bronchiol
requir
fluid
replac
therapi
howev
lack
agreement
method
fluid
replac
use
nasogastr
feed
may
consid
child
decreas
oral
intak
mild
moder
respiratori
distress
respiratori
rate
exce
breath
per
minut
increas
risk
food
aspir
lung
point
intraven
fluid
consid
maintain
hydrat
evid
determin
optim
rout
fluid
replac
infant
bronchiol
current
inadequ
larg
random
multicent
trial
plan
australian
pediatr
emerg
research
collabor
may
provid
definit
answer
clinic
set
measur
reduc
oxygen
satur
result
use
supplement
oxygen
one
major
determin
hospit
admiss
length
stay
interestingli
studi
examin
effect
oxygen
clinic
recoveri
bronchiol
recent
cochran
collabor
review
oxygen
therapi
lower
respiratori
tract
infect
children
identifi
singl
trial
compar
oxygen
therapi
versu
oxygen
supplement
date
clear
direct
constitut
safe
admiss
discharg
hemoglobin
oxygen
satur
level
aap
recommend
supplement
oxygen
hemoglobin
oxygen
satur
persist
suggest
point
discontinu
oxygen
therapi
child
oxygen
satur
maintain
room
air
child
feed
well
minim
respiratori
distress
prematur
low
birth
weight
infant
well
chronic
lung
diseas
congenit
heart
diseas
may
requir
consider
administ
discontinu
oxygen
children
like
lower
toler
hypoxemia
higher
likelihood
sever
diseas
children
bronchiol
often
suffer
copiou
thick
nasal
secret
young
age
preclud
effect
selfclear
nasal
passag
nasal
suction
commonli
use
home
hospit
set
make
intuit
sens
continu
practic
knowledg
singl
trial
assess
effect
nasal
suction
bronchiol
might
thought
chest
physiotherapi
would
improv
clearanc
secret
associ
bronchiol
decreas
ventilatori
effort
howev
recent
cochran
review
three
clinic
trial
percuss
vibrat
techniqu
use
chest
physio
therapi
infant
versu
intervent
support
routin
use
review
conclud
nonventil
infant
bronchiol
chest
physiotherapi
reduc
length
hospit
stay
oxygen
requir
improv
clinic
sever
score
bronchodil
commonli
use
manag
bronchiol
north
america
howev
evid
support
practic
strong
practic
remain
controversi
cochran
review
trial
compar
bronchodil
epinephrin
use
placebo
bronchiol
includ
data
infant
studi
oral
inhal
shortact
agonist
includ
statist
signific
clinic
modest
improv
overal
averag
clinic
score
patient
treat
bronchodil
note
improv
oxygen
appear
bronchodil
greater
effect
outpati
set
rather
hospit
set
howev
patient
receiv
bronchodil
show
improv
hospit
rate
durat
hospit
author
review
note
effect
bronchodil
bronchiol
may
overestim
mani
review
studi
includ
patient
recurr
wheez
group
thought
clinic
differ
acut
bronchiol
overal
would
appear
shortact
agonist
provid
best
modest
transient
relief
clear
benefit
hospit
rate
durat
hospit
aap
recommend
bronchodil
routin
use
manag
bronchiol
conced
care
monitor
trial
inhal
shortact
agonist
consid
use
continu
benefici
clinic
respons
document
anoth
commonli
use
bronchodil
treatment
bronchiol
nebul
epinephrin
adrenalin
shortact
agonist
aap
recommend
nebul
epinephrin
routin
use
manag
bronchiol
cochran
review
nebul
epinephrin
bronchiol
review
trial
includ
inpati
outpati
inpati
trial
n
clinic
score
improv
epinephrin
group
oxygen
satur
admiss
rate
differ
outpati
studi
n
demonstr
shortterm
improv
clinic
score
oxygen
respiratori
rate
overal
improv
patient
seven
trial
compar
epinephrin
salbutamol
inpati
outpati
set
appear
epinephrin
might
prefer
drug
outpati
howev
insuffici
evid
recommend
epinephrin
use
inpati
set
care
monitor
trial
epinephrin
perform
individu
patient
use
continu
document
posit
clinic
respons
note
decis
made
test
inhal
bronchodil
current
state
evid
would
seem
support
trial
epinephrin
first
appear
slightli
greater
effect
agonist
howev
given
fact
epinephrin
avail
use
home
set
aap
suggest
agonist
trial
might
appropri
clinic
nonhospit
set
corticosteroid
administ
via
inhal
system
via
oral
intramuscular
intraven
rout
infant
admit
hospit
receiv
corticosteroid
therapi
mani
therapi
bronchiol
use
corticosteroid
controversi
system
corticosteroid
use
bronchiol
long
hotli
debat
topic
recent
complet
cochran
review
conduct
includ
trial
total
infant
overal
use
system
corticosteroid
demonstr
benefit
review
conclud
glucocorticoid
significantli
reduc
patient
visit
length
stay
inpati
interestingli
recent
larg
multicent
random
trial
n
infant
examin
emerg
depart
use
oral
corticosteroid
nebul
epinephrin
prevent
hospit
admiss
studi
demonstr
possibl
synergist
effect
combin
two
medic
treatment
bronchiol
demonstr
reduc
hospit
admiss
well
shorten
time
discharg
durat
clinic
symptom
bronchodil
glucocorticoid
synergi
phenomenon
well
document
agoniststeroid
use
asthma
also
recent
seen
smaller
bronchiol
studi
consid
synergi
epinephrin
oral
glucocorticoid
studi
consid
exploratori
result
unexpect
studi
requir
confirm
find
role
inhal
glucocorticoid
use
infant
bronchiol
examin
systemat
review
determin
effect
prevent
postbronchiol
wheez
five
studi
includ
infant
includ
analys
fail
demonstr
effect
wheez
hospit
readmiss
rate
use
bronchodil
author
note
strength
recommend
neg
affect
small
number
particip
clinic
divers
studi
two
known
studi
investig
role
inhal
glucocorticoid
treatment
acut
symptom
diseas
neither
demonstr
benefit
current
evid
support
use
inhal
corticosteroid
acut
longterm
benefit
bronchiol
sinc
known
mucou
plug
play
signific
role
small
airway
obstruct
bronchiol
would
seem
reason
intervent
might
thin
airway
secret
could
improv
clinic
outcom
inhal
hyperton
salin
deoxyribonucleas
dnase
two
intervent
success
use
cystic
fibrosi
consid
bronchiol
therapi
exact
mechan
action
remain
unclear
nebul
hyperton
salin
thought
improv
mucociliari
clearanc
caus
osmot
movement
water
airway
recent
cochran
review
effect
hyperton
salin
review
four
trial
total
infant
inpati
outpati
three
trial
use
hyperton
salin
combin
either
nebul
epinephrin
two
studi
terbutalin
studi
remain
trial
use
nebul
hyperton
salin
alon
overal
patient
treat
nebul
hyperton
salin
significantli
shorter
mean
length
hospit
stay
almost
full
day
improv
clinic
sever
score
compar
receiv
nebul
normal
salin
also
demonstr
advers
effect
use
recent
emerg
departmentbas
random
trial
hyperton
salin
bronchiol
includ
review
would
suggest
effect
hyperton
salin
seen
immedi
trial
demonstr
effect
clinic
sever
first
hour
posttreat
safeti
efficaci
evid
use
hyperton
salin
compel
trial
review
small
given
lack
advers
event
possibl
improv
outcom
seem
reason
suggest
use
hyperton
salin
acut
bronchiol
one
plan
use
hyperton
salin
current
best
recommend
would
begin
use
earli
expect
benefici
effect
would
seen
immedi
postus
dnase
enhanc
mobil
mucu
liquefi
mucou
plug
contain
larg
amount
lyse
inflammatori
cell
dna
airway
two
trial
dnase
bronchiol
report
current
literatur
date
dnase
found
effect
length
stay
clinic
sever
score
durat
oxygen
therapi
leukotrien
thought
contribut
airway
inflammatori
respons
bronchiol
thu
role
leukotrien
modifi
explor
ill
one
small
trial
n
daili
oral
montelukast
versu
placebo
fail
demonstr
differ
length
stay
clinic
sever
score
cytokin
level
larg
trial
infant
rsvposit
infant
random
receiv
either
oral
montelukast
placebo
studi
montelukast
improv
respiratori
symptom
postrsv
bronchiol
children
current
insuffici
evid
recommend
leukotrien
modifi
use
bronchiol
heliox
mixtur
oxygen
helium
use
treatment
acut
asthma
exacerb
sinc
limit
number
studi
heliox
use
bronchiol
emerg
last
two
decad
mechan
action
heliox
inhal
therapi
clearli
understood
propos
decreas
work
breath
wheez
occur
heliox
use
might
due
increas
flow
rate
less
turbul
flow
ultim
result
better
ventil
distal
alveoli
heliox
therapi
tradit
reserv
sickest
patient
recent
cochran
review
heliox
therapi
bronchiol
identifi
four
intens
care
unit
icu
trial
modest
total
number
patient
n
patient
benefit
significantli
lower
mean
clinic
score
first
hour
postheliox
therapi
versu
air
oxygen
therapi
clinic
signific
reduct
rate
intub
need
mechan
ventil
length
stay
icu
present
enough
evid
routin
recommend
use
heliox
therapi
sever
ill
children
bronchiol
evid
use
mild
moder
ill
infant
ribavirin
inhal
broadspectrum
antivir
agent
sometim
albeit
controversi
use
treatment
sever
ill
highrisk
infant
bronchiol
antivir
agent
licens
use
rsv
bronchiol
shown
provid
limit
clinic
benefit
cochran
review
twelv
ribavirin
trial
infant
rsv
lower
respiratori
tract
infect
determin
use
may
decreas
number
day
hospit
mechan
ventil
howev
ribavirin
reduc
respiratori
deterior
mortal
routin
use
ribavirin
recommend
children
bronchiol
studi
limit
drug
difficult
administ
potenti
toxic
despit
bronchiol
recogn
viral
ill
antimicrobi
commonli
prescrib
reason
cite
antimicrobi
use
includ
high
fever
young
age
concern
bacteri
superinfect
cochran
review
use
antimicrobi
bronchiol
identifi
one
trial
ampicillin
versu
placebo
demonstr
differ
durat
ill
death
two
group
recent
moderates
studi
n
antimicrobi
use
infant
bronchiol
demonstr
clinic
advantag
use
antimicrobi
care
children
author
conclud
support
measur
without
antimicrobi
remain
standard
care
hospit
set
given
result
studi
low
rate
seriou
bacteri
coinfect
children
bronchiol
routin
use
antimicrobi
recommend
recent
explor
effect
macrolid
antimicrobi
lower
respiratori
tract
diseas
macrolid
therapi
thought
exert
effect
three
potenti
mechan
antimicrobi
direct
bacteri
kill
action
indirect
bacteri
modul
antigastroesophag
reflux
via
promotil
effect
antiinflammatori
alter
releas
action
proinflammatori
cytokin
current
studi
exist
use
macrolid
bronchiol
obliteran
cystic
fibrosi
bronchiectasi
recent
small
studi
n
clarithromycin
use
acut
bronchiol
suggest
macrolid
statist
signific
effect
length
stay
use
agonist
plasma
level
inflammatori
marker
current
role
routin
use
macrolid
therapi
acut
viral
bronchiol
role
remain
clarifi
futur
research
support
care
fail
lead
improv
clinic
statu
child
moder
sever
respiratori
distress
respiratori
exhaust
failur
immin
assist
ventil
next
step
endotrach
intub
mechan
ventil
timehonor
intervent
howev
mechan
ventil
without
risk
complic
clinician
research
consid
nasal
continu
posit
airway
pressur
ncpap
less
invas
altern
ventil
propos
mechan
action
ncpap
bronchiol
includ
pneumat
splint
effect
expand
airway
diamet
improv
air
flow
exhal
decreas
work
breath
evid
quit
limit
use
cpap
one
trial
identifi
recent
review
topic
found
evid
use
ncpap
bronchiol
lead
lower
rate
mechan
ventil
possibl
howev
earli
use
ncpap
moder
sever
bronchiol
may
lead
modest
improv
cardiorespiratori
paramet
review
evid
treatment
bronchiol
quickli
becom
clear
mani
modal
treatment
avail
mani
possibl
approach
therapi
nearexponenti
increas
evid
opinion
advic
regard
treatment
bronchiol
coupl
demand
everyday
clinic
practic
make
challeng
averag
health
care
profession
keep
abreast
latest
approach
clinic
pathway
aim
link
evid
practic
conditionspecif
manner
therebi
optim
patient
outcom
clinic
efficaci
studi
specif
bronchiol
show
implement
evidencebas
guidelin
result
decreas
use
unnecessari
nasopharyng
viru
test
chest
radiograph
bronchodil
report
studi
rate
admiss
decreas
mean
length
stay
decreas
mean
cost
respiratori
care
servic
decreas
clinic
guidelin
provid
gener
recommend
clinic
pathway
outlin
specif
step
timefram
realiz
said
recommend
recent
elabor
cochran
review
studi
involv
patient
suggest
use
clinic
pathway
gener
associ
reduc
inhospit
complic
improv
document
without
neg
impact
length
stay
hospitalbas
cost
clear
criteria
determin
hospit
children
bronchiol
hospit
consid
infant
respiratori
rate
greater
breath
per
minut
hemoglobin
oxygen
satur
less
histori
apnea
letharg
dehydr
factor
may
influenc
disposit
determin
includ
prematur
young
age
preexist
cardiopulmonari
diseas
immunodefici
neuromuscular
disord
infant
social
situat
caregiv
exhaust
also
play
role
decis
make
recent
publish
abstract
identifi
gestat
age
heart
rate
respiratori
rate
respiratori
distress
assess
instrument
score
oxygen
satur
room
air
significantli
associ
develop
sever
bronchiol
cohort
canadian
infant
bronchiol
util
variabl
predict
need
admiss
yet
determin
frequent
thorough
consist
hand
hygien
shown
reduc
nosocomi
spread
rsv
key
infectioncontrol
principl
health
care
set
home
rsv
virus
spread
secret
hand
contact
fomit
virus
includ
rsv
found
secretioncontamin
bed
toy
crib
rail
tabletop
organ
remain
viabl
mani
hour
center
diseas
control
prevent
publish
detail
evidencebas
recommend
regard
hand
hygien
antisepsi
health
care
set
note
recommend
hand
decontamin
prior
direct
contact
patient
contact
inanim
object
direct
vicin
patient
remov
glove
hand
hygien
antimicrobi
soap
recommend
visibl
dirti
hand
otherwis
alcoholbas
rub
prefer
current
vaccin
exist
prevent
rsv
infect
predomin
etiolog
agent
bronchiol
develop
success
vaccin
challeng
immun
multipl
strain
viru
would
requir
one
would
expect
seri
booster
would
necessari
vaccin
effect
natur
infect
viru
confer
longterm
immun
passiv
immun
rsv
accomplish
develop
two
differ
product
use
current
recommend
infant
consid
high
risk
develop
sever
rsv
bronchiol
american
academi
pediatr
subcommitte
manag
treatment
bronchiol
outlin
group
infant
consid
high
risk
sever
rsv
complic
recommend
palivizumab
tabl
rsv
immun
globulin
rsvig
first
form
immunoprophylaxi
becom
avail
expens
therapi
requir
administr
larg
volum
mlkg
fluid
long
period
time
hour
moder
size
n
subject
random
blind
multicent
trial
rsvig
increas
incid
advers
event
subgroup
infant
congenit
heart
diseas
thu
rsvig
recommend
group
palivizumab
human
monoclon
antibodi
becom
passiv
immun
agent
choic
administ
monthli
intramuscular
inject
peak
month
rsv
season
larg
n
subject
random
doubleblind
multicent
trial
palivizumab
associ
reduct
rsvrelat
hospit
fewer
overal
day
hospit
lower
rate
icu
admiss
find
confirm
similar
result
studi
children
signific
congenit
heart
diseas
eas
administr
lack
interfer
routin
immun
main
consider
choos
palivizumab
rsvig
unfortun
palivizumab
quit
expens
estim
cost
per
season
econom
analys
rsv
immunoprophylaxi
fail
demonstr
overal
save
health
care
expenditur
larg
financi
cost
immun
atrisk
infant
main
advantag
palivizumab
relat
decreas
rsvrelat
hospit
date
none
five
clinic
random
control
trial
demonstr
signific
decreas
rate
mortal
attribut
receiv
rsv
immun
prophylaxi
major
infant
infect
rsv
bronchiolitiscaus
virus
develop
mild
urti
first
day
ill
urti
manifest
progress
lower
respiratori
tract
involv
bronchiol
wheez
crackl
vari
degre
respiratori
distress
mean
durat
ill
day
major
infect
resolv
unev
within
week
note
infant
bronchiol
remain
symptomat
day
ill
recent
prospect
cohort
studi
highlight
prolong
diseas
cours
acut
ill
epidemiolog
studi
indic
high
degre
morbid
bronchiol
low
mortal
last
decad
appear
mortal
remain
stabl
bronchiol
children
hospit
bronchiol
mortal
rate
estim
around
rate
high
children
underli
cardiac
chronic
lung
condit
overal
rate
hospit
increas
bronchiol
apnea
risk
apnea
caus
concern
caregiv
health
care
profession
alik
often
lead
hospit
rate
apnea
rsv
bronchiol
rang
recent
systemat
review
would
appear
rate
apnea
previous
healthi
term
infant
less
infant
risk
factor
eg
prematur
congenit
heart
diseas
carri
greater
risk
occurr
occurr
prolong
recurr
apnea
consider
regard
intub
patient
risk
requir
intub
hospit
children
bronchiol
estim
approxim
studi
identifi
children
bronchiol
may
concomit
acut
otiti
media
unfortun
clinic
featur
reliabl
distinguish
viral
bacteri
ear
infect
tympanocentesi
reliabl
accomplish
differenti
consid
impract
averag
clinician
engag
practic
identifi
acut
otiti
media
best
treat
per
wellrecogn
aap
american
academi
famili
physician
guidelin
seriou
bacteri
infect
includ
bacteremia
urinari
tract
infect
mening
concern
evalu
febril
infant
includ
bronchiol
number
studi
shown
febril
infant
diagnos
rsv
infect
significantli
lower
risk
seriou
bacteri
infect
compar
children
without
rsv
infect
child
bacteri
infect
like
urinari
tract
infect
vey
young
febril
infant
younger
month
age
bronchiol
requir
care
assess
sourc
fever
febril
infant
younger
week
age
clinician
would
perform
full
septic
workup
includ
blood
cultur
blood
count
cathet
urin
sampl
chest
radiograph
lumbar
punctur
mani
would
consid
least
partial
full
septic
workup
infant
week
month
age
report
children
inappropri
secret
antidiuret
hormon
associ
bronchiol
kept
mind
monitor
fluid
statu
measur
serum
sodium
level
perform
appropri
infant
receiv
intraven
fluid
varieti
cardiac
manifest
rsv
note
includ
myocard
arrhythmia
complet
heart
block
sepsislik
syndrom
absenc
secondari
bacteri
infect
also
known
occur
children
rsv
infect
extrapulmonari
manifest
sever
rsv
infect
includ
focal
gener
seizur
focal
neurolog
find
hepat
hospit
major
notabl
outcom
sever
bronchiol
outcom
also
longerterm
complic
includ
bronchiol
obliteran
allerg
sensit
develop
wheez
arguabl
asthma
later
life
studi
attempt
link
bronchiol
infanc
allerg
sensit
atop
ill
yet
produc
clear
answer
studi
demonstr
associ
two
entiti
other
bronchiol
obliteran
rare
fibros
form
chronic
obstruct
lung
diseas
follow
sever
insult
lower
respiratori
tract
see
chapter
first
describ
lang
bronchiol
obliteran
result
partial
complet
obliter
small
airway
fig
exact
incid
childhood
bronchiol
obliteran
known
etiolog
adult
form
bronchiol
obliteran
includ
inhal
injuri
hypersensit
pneumon
posttranspl
autoimmun
disord
contrast
childhood
bronchiol
obliteran
often
seen
sever
lower
respiratori
tract
infect
common
associ
viral
etiolog
adenoviru
especi
serotyp
howev
suggest
rsv
may
caus
well
tabl
outlin
vari
possibl
etiolog
pediatr
bronchiol
obliteran
chain
event
lead
bronchiol
obliteran
like
begin
injuri
epitheli
cell
airway
caus
transient
derang
cell
function
necrosi
local
necrosi
lead
intralumin
accumul
fibrinopurul
exud
induc
overgrowth
expos
myofibroblast
denud
submucosa
myofibroblast
hyperprolifer
lead
collagen
acid
mucopolysaccharid
deposit
result
narrow
bronchiol
occasion
larg
intralumin
polyp
known
masson
bodi
may
develop
secondari
histiocyt
capillari
prolifer
clinic
present
bronchiol
obliteran
may
mimic
acut
viral
bronchiol
often
without
fever
rhinorrhea
older
patient
may
complain
dyspnea
cough
decreas
exercis
toler
physic
find
quit
nonspecif
expiratori
wheez
crackl
may
heard
occas
postinfecti
set
infant
may
appear
partial
recov
acut
ill
persist
respiratori
symptom
typic
respiratori
find
persist
day
chest
radiograph
demonstr
dramat
hyperinfl
bilater
increas
interstiti
mark
bronchiol
obliteran
accur
diagnos
microscop
examin
adequ
biopsi
materi
transthorac
biopsi
two
tissu
site
sampl
current
recommend
definit
diagnosi
invas
natur
type
diagnost
test
criteria
creat
reflect
bronchiol
obliteran
syndrom
take
account
pulmonari
function
test
surrog
graft
dysfunct
lung
transplant
recipi
highresolut
ct
becom
import
test
diagnosi
bronchiol
obliteran
mosaic
perfus
vascular
attenu
central
bronchiectasi
key
featur
morbid
mortal
bronchiol
obliteran
remain
uncertain
postadenoviru
bronchiol
obliteran
seem
low
mortal
high
chronic
occas
gradual
resorpt
fibrovascular
connect
tissu
occur
restor
normal
airway
calib
epithelium
treatment
bronchiol
obliteran
children
often
difficult
unsuccess
azithromycin
macrolid
antimicrobi
appear
effect
treatment
bronchiol
obliteran
presum
act
via
postul
antiinflammatori
effect
corticosteroid
shown
improv
outcom
experiment
therapi
includ
immunomodul
monoclon
antibodi
direct
receptor
aerosol
cyclosporin
ultim
option
children
sever
bronchiol
obliteran
lung
transplant
one
third
children
postinfecti
bronchiol
obliteran
develop
swyerjam
syndrom
macleod
syndrom
diagnos
adulthood
longterm
complic
postinfecti
constrict
bronchiol
childhood
also
associ
adenoviru
pneumonia
bronchiol
syndrom
describ
develop
unilater
hyperluc
lung
decreas
vascular
increas
air
trap
evid
plain
radiograph
develop
due
postinfecti
fibrot
heal
immatur
lung
lead
decreas
number
alveoli
pulmonari
vessel
imag
swyerjam
syndrom
demonstr
diffus
asymmetr
patchi
lobar
lobular
air
trap
almost
often
bilater
fig
routin
use
ct
scan
believ
syndrom
unilater
phenomenon
sinc
disprov
